INGREZZA® (valbenazine) capsules is a once-daily treatment for adults with tardive dyskinesia and adults with chorea associated with Huntington’s disease.
TakING control.
INGREZZA is highly effective.
Uniquely selective.1
From the start.
Actor portrayal
INGREZZA is highly effective.
Uniquely selective.1
UNIQUELY
SELECTIVE
Only INGREZZA exclusively delivers one primary metabolite (+ α) for potent and selective inhibition of VMAT21-3,*
EXPLOREPHARMACOLOGY
PROVEN
EFFICACY
INGREZZA 80 mg reduced TD severity in 7 of 10 patients at 6 weeks (post hoc analysis)1,4,†
REVIEW TD EFFICACY
SIMPLE FROM
THE START
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
EXPLORE DOSINGSAVINGS &
SUPPORT
$10 or less out-of-pocket is what most patients pay for INGREZZA5
SEE SUPPORT OPTIONS* | Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and the primary active metabolite of INGREZZA, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes. |
† | Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score. |
HD CHOREA
Rapid and sustained chorea reductions observed with
INGREZZA as early as Week 2 and through Week 121,6,‡
‡Change in Total Maximal Chorea score vs placebo from baseline through end of treatment (average of Weeks 10 and 12).
HD CHOREA
Rapid and sustained chorea reductions observed with INGREZZA as early as Week 2 and through Week 121,6,‡
REVIEW HD CHOREA EFFICACY‡Change in Total Maximal Chorea score vs placebo from baseline through end of treatment (average of Weeks 10 and 12).
CONNECT WITH A
REPRESENTATIVE
Request an office visit from a Neurocrine representative for additional information, patient resources, or samples of INGREZZA.
CONTACT A REPREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
- Data on file. Neurocrine Biosciences, Inc.
- Measured by NDC; data on file as of Q3 2023. Neurocrine Biosciences, Inc.
- Stimming EF, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504.
- Data on file as of Q3 2023. Neurocrine Biosciences, Inc.